Akero Therapeutics Inc. | Mid-cap | Healthcare
$51.77
-0.21%
| Akero Therapeutics Stock Comparison:
Akero Therapeutics vs VertexAkero Therapeutics vs RegeneronAkero Therapeutics vs Blueprint MedicinesAkero Therapeutics vs Roivant SciencesAkero Therapeutics vs Bio-TechneAkero Therapeutics vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 0
Operating Income -285.4M
Net Income -252.1M

Balance Sheet Metrics

Total Assets 825.9M
Total Liabilities 75.8M
Shareholders Equity 750.1M
Debt to Equity 0.10

Cash Flow Metrics

Operating Cash Flow -218.7M
Free Cash Flow -231.1M

Revenue & Profitability Trend

Akero Therapeutics Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue 0 0 0 0 0
Cost of Goods Sold - - - - -
Gross Profit - - - - -
Operating Expenses 285.4M 172.9M 115.2M 100.9M 80.2M
Operating Income -285.4M -172.9M -115.2M -100.9M -80.2M
Pre-tax Income -252.1M -151.8M -112.0M -100.8M -79.2M
Income Tax - - - - -
Net Income -252.1M -151.8M -112.0M -100.8M -79.2M
EPS (Diluted) - -$2.89 -$2.87 -$2.89 -$2.52

Income Statement Trend

Akero Therapeutics Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets 770.4M 560.0M 355.2M 193.6M 271.3M
Non-Current Assets 55.5M 20.3M 1.4M 2.0M 2.0M
Total Assets 825.9M 580.3M 356.6M 195.5M 273.3M
Liabilities
Current Liabilities 39.8M 19.1M 19.1M 25.1M 13.1M
Non-Current Liabilities 36.0M 25.8M 10.9M 1.3M 1.5M
Total Liabilities 75.8M 45.0M 30.0M 26.4M 14.6M
Equity
Total Shareholders Equity 750.1M 535.3M 326.6M 169.1M 258.7M

Balance Sheet Composition

Akero Therapeutics Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income -252.1M -151.8M -112.0M -100.8M -79.2M
Operating Cash Flow -218.7M -130.1M -87.6M -87.4M -70.6M
Investing Activities
Capital Expenditures - - - 0 -148.0K
Investing Cash Flow -108.7M -223.6M -63.8M 42.3M -9.8M
Financing Activities
Dividends Paid - - - - -
Financing Cash Flow 432.2M 349.7M 250.3M -521.0K 202.6M
Free Cash Flow -231.1M -145.4M -92.5M -79.7M -71.0M

Cash Flow Trend

Akero Therapeutics Key Financial Ratios

Valuation Ratios

Forward P/E -12.75
Price to Book 3.98
PEG Ratio -12.75

Profitability Ratios

Profit Margin 0.00%
Operating Margin 0.00%
Return on Equity -27.92%
Return on Assets -18.52%

Financial Health

Current Ratio 16.80
Debt to Equity 3.34
Beta -0.16

Per Share Data

EPS (TTM) -$3.75
Book Value per Share $13.60

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
akro 4.3B - 3.98 -27.92% 0.00% 3.34
Vertex 114.1B 32.82 6.92 -5.64% -8.91% 10.00
Regeneron 55.3B 13.02 1.84 15.96% 31.94% 9.20
Blueprint Medicines 8.3B -120.00 24.19 -47.71% -27.70% 208.50
Roivant Sciences 7.8B 1.95 1.71 -12.54% 96.86% 1.93
Bio-Techne 7.9B 60.87 3.92 6.53% 10.89% 20.99

Financial data is updated regularly. All figures are in the company's reporting currency.